Ryne Biotechnology has been awarded $4 million to advance RNDP-001, its investigational dopamine-producing, or dopaminergic, neuron replacement therapy for Parkinson’s disease. The funding comes in the form of a Clinical Stage Research Program grant from the California Institute for Regenerative Medicine (CIRM). Ryne plans to use the award…
Cerevance is planning to launch a Phase 2 clinical trial in the second quarter of this year to test its experimental oral medication CVN424 in people newly diagnosed with Parkinson’s disease. The company announced $51 million in new funding, from an expanded round of Series B Financing, for…
“Parkinson’s Science POV,” a limited series podcast by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), has garnered silver and Listener’s Choice honors at the Signal Awards’ inaugural program. The awards, honoring top 2022 podcasts globally, recognized the Parkinson’s disease series within its Science & Education category for “Limited Series…
Scientists have identified potential biomarkers for the early detection of Parkinson’s disease in certain people carrying a common disease mutation. Specifically, they found that a combination of four small RNA molecules, called microRNAs (miRNAs), in the blood may help predict disease onset in people who carry a Parkinson’s-associated LRRK2…
IntelGenx has teamed up with a renowned neurologist at the Karolinska Institute, Sweden to conduct a clinical trial on Montelukast VersaFilm, its proprietary oral thin film formulation, in people with Parkinson’s disease. The multicenter trial, expected to start between July and September, will be led by Per Svenningsson,…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a $2.5 million research grant to advance the development of Soturi, Newel Health’s digital therapeutic app designed to help patients optimize their personalized treatment plan. The Soturi app is designed to deliver services to people with…
A Phase 3 clinical trial of Annovis Bio‘s investigational oral treatment buntanetap in people with early-stage Parkinson’s disease now will open to patients in Europe. This expansion will add 48 new trial sites in Italy, Spain, Hungary, Poland and Germany, joining about 50 sites actively recruiting in the U.S.
Mindfulness meditation — a mental training of being focused on the present moment without interpretation or judgment — was better than physical exercise at lessening depression symptoms and maintaining emotional stability in people with mild-to-moderate Parkinson’s disease. That’s according to data from a small clinical trial conducted in Hong…
AC Immune has been awarded two research grants to identify the presence of TDP-43, a protein that plays a key role in neurodegeneration underlying Parkinson’s disease and other neurological diseases. The grants were awarded by the Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Target…
Dosing has begun in a Phase 1 clinical trial of healthy volunteers to evaluate the safety and pharmacological properties of NEU-723, Neuron23’s oral investigational treatment for Parkinson’s disease. The small molecule candidate therapy is designed to block LRRK2, an enzyme coded by a gene of the same name whose…
Get regular updates to your inbox.
